Lilly Makes Billions of Weight-Loss Pills
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback